Please login to the form below

Not currently logged in
Email:
Password:

Manish Singh resigns as CEO of ImmunoCellular Therapeutics

Replaced on interim basis by company chair and chief scientific officer Dr John Yu

John Yu - ImmunoCellularDr Manish Singh has stepped down as CEO of ImmunoCellular Therapeutics to be replaced by the company's founder Dr John Yu (pictured) on an interim basis.

US-based cancer specialist ImmunoCellular said that Dr Singh has left to "pursue other opportunities" having joined as president and CEO of the company in February 2008.

In that time, the company has focused on its lead candidate ICT-107, a cell-based vaccine in phase II development to target glioblastoma brain tumours.

The drug's progress will now be overseen by Dr Yu, who asserted his confidence in the treatment's potential, as well as ImmunoCellular's other pipeline products.

“We hope that this trial will provide clinical validation of our platform and represent a potential breakthrough treatment for this deadly and intractable cancer," he said.

“We intend to continue to make progress in advancing our earlier stage product candidates, with the recent approval of an IND to initiate a phase I trial of ICT-121 targeting CD133-positive cancer stem cells. We are developing a phase I study with ICT-140 to treat ovarian cancer.”

Dr Yu is the chief scientific officer and chair of ImmunoCellular in addition to serving on the faculty of the Department of Neurosurgery at Cedars-Sinai Medical Center.

He will continue as interim CEO while a search for a permanent replacement for Dr Singh is carried out.

22nd August 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GCI Health

GCI Health is an integrated communications agency designed for and inspired by the ever-changing face of healthcare. In London, we...

Latest intelligence

The ALS patient journey
Nick Goldup is the Director of Care Improvement at the Motor Neuron Disease Association (MNDA). Here, he offers his insights into the journey for patients with ALS and explores the...
Equipping your medical affairs teams with solutions to navigate the healthcare landscape
Dr Tyler Ray, OPEN Health Medical Communications...
Protein degraders
Can protein degraders unlock ‘undruggable’ drug targets?
Exploring a new and exciting area of small-molecule drug discovery...

Infographics